局部治疗在银屑病患者旅程中的作用:2021年第30届EADV大会「根据患者需求与期望定制局部银屑病治疗」研讨会概述
本文概述第30届欧洲皮肤病与性病学大会卫星研讨会上关于局部治疗在银屑病患者旅程中作用的报告,重点讨论当前未满足需求与数据缺口。约70%-80%患者为轻中度银屑病,可用局部药物成功治疗;德国推荐轻度银屑病患者起始局部治疗联合护肤产品。CAL/BDP固定复方在德国、西班牙和英国是超出轻度患者最常处方的局部治疗。
要点
- 约70%-80%银屑病患者为轻中度,可用局部药物成功治疗。
- 德国推荐轻度银屑病患者起始局部治疗联合护肤产品。
- CAL/BDP固定复方是德西英超出轻度患者最常处方局部治疗。
核心结论
- 局部治疗是银屑病管理的基石,约70%-80%的轻中度患者可经局部药物成功治疗。
- 局部治疗在重度银屑病中也可有效,但无效、患者不满意和依从性仍是治疗成功的最大障碍。
研究设计与样本
- 本文为第30届欧洲皮肤病与性病学大会卫星研讨会上题为「局部治疗在银屑病患者旅程中的作用」的报告概述。
主要发现
- 约70%-80%的患者表现为轻中度银屑病,可用局部药物成功治疗。
- 在德国、西班牙和英国的真实世界环境中,钙泊三醇/二丙酸倍他米松(CAL/BDP)固定复方是超出轻度患者最常处方的局部治疗。
- 医护人员在某些情况下经常或非常经常将局部药物作为非生物系统治疗的替代,如患者偏好(51%)、禁忌证(50%)和限制副作用(26%)。
- 局部治疗的主要优势包括多种局部成分和外用制剂可选、适应不同解剖部位、可与光疗和系统治疗联合。
关键数值与推荐
- 根据德国一项推荐,轻度银屑病患者应起始局部治疗联合护肤产品。
- 患者偏好(51%)、禁忌证(50%)和限制副作用(26%)是医护人员经常或非常经常将局部药物作为非生物系统治疗替代的情况。
临床怎么用
- 局部治疗是银屑病管理的基石,约70%-80%的轻中度患者可经局部药物成功治疗。
- 根据德国一项推荐,轻度银屑病患者应起始局部治疗联合护肤产品。
- 使用系统治疗的患者可加用局部治疗以优化治疗结果和改善生活质量。
- 特定情况下的患者(如妊娠或手术)可受益于转换为局部治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article summarizes a presentation titled 'The role of topical therapies along the psoriasis patient journey' held at the Satellite Symposium of the 30th European Academy of Dermatology and Venereology Congress. During this session, the role of topical treatments in the management of psoriasis was presented, with a particular focus on the current unmet needs and data gaps. Psoriasis plays a significant role in a patient's daily life, impacting them not only physically but also psychologically and socially. The disease burden increases with duration and severity. Topical therapies are the keystone of the management of psoriasis. About 70%-80% of patients present a mild-to-moderate form of psoriasis that can be successfully treated with topical agents. According to a German recommendation, patients with mild psoriasis should initiate a topical therapy in combination with skin care products. In the real-life setting, the calcipotriol/betamethasone dipropionate (CAL/BDP) fixed combination was the most prescribed topical treatment for beyond-mild patients in Germany, Spain and the United Kingdom. Healthcare professionals also often or very often prescribed topicals as an alternative to non-biologic systemics in certain situations, such as patient preference (51%), contraindication (50%) and to limit side effects (26%). Adjunctive topical therapy to patients using systemic therapy is used to optimize treatment outcomes and improving the quality of life for patients. Topical treatments can be also effective in severe forms of psoriasis. However, there are still some gaps and unmet needs on topical therapy. Ineffectiveness, patient dissatisfaction and adherence are the largest barriers to treatment success. Main strengths of topical treatments include the availability of various topical ingredients and galenics, the adaptability to different anatomical areas and the possible combination with phototherapy and systemics. Moreover, patients in specific situations can benefit from switching to topical treatments (e.g. pregnancy or surgery).
引用
- Pinter A, van de Kerkhof P. The role of topical therapies along the psoriasis patient journey: An overview from the Symposium 'Tailoring topical psoriasis treatments to patients' needs and expectations' of the 30th EADV Congress 2021. J Eur Acad Dermatol Venereol. 2023. PMID: 36546464. doi:10.1111/jdv.18761
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。